The Latest News
Newsroom
The latest from Cartography. Explore our scientific publications, press releases, and media coverage as we build a new engine for cell-specific drug discovery.
A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214
Scientific Publications
May 27, 2026
Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline
Press Releases
May 6, 2026
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead's First Option Target Exercise
Press Releases
April 9, 2026
Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer
Press Releases
February 24, 2026
Cartography does another pharma deal, this time with Pfizer
Media Coverage
January 6, 2026
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens
Press Releases
January 6, 2026
Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer
Press Releases
December 18, 2025
Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic
Press Releases
October 2, 2025
Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline
Press Releases
May 6, 2026
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead's First Option Target Exercise
Press Releases
April 9, 2026
Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer
Press Releases
February 24, 2026
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens
Press Releases
January 6, 2026
Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer
Press Releases
December 18, 2025
Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic
Press Releases
October 2, 2025
Cartography Names Dirk Nagorsen, M.D., as Chief Medical Officer in Expansion of Its Clinical Team
Press Releases
September 3, 2025
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors
Press Releases
October 29, 2024
Cartography does another pharma deal, this time with Pfizer
Media Coverage
January 6, 2026
AI deals show no sign of slowing
Media Coverage
June 2, 2025
Finding New Targets for Cancer Drugs: Kevin Parker on the Long Run
Media Coverage
April 14, 2025
Cartography Biosciences and Nested Therapeutics: Diamonds in the rough
Media Coverage
October 2, 2023
Precision target discovery at forefront for immunotherapy startup Cartography
Media Coverage
July 5, 2023
Cartography Biosciences unearths cancer immunotherapy targets
Media Coverage
September 22, 2022
On the Map: Cartography Charts a Course for Precision Cancer Treatments
Media Coverage
September 6, 2022
Investing in Cartography Biosciences
Media Coverage
July 19, 2022
A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214
Scientific Publications
May 27, 2026
LY6G6D targeting with a T cell engager is a promising therapeutic for MSS colorectal cancer
Scientific Publications
April 21, 2025
Identifying optimal tumor-associated antigen combinations with single-cell genomics to enable multi-targeting therapies
Scientific Publications
November 6, 2024
A CB21-targeted T cell engager is a promising therapeutic for the treatment of colorectal cancer
Scientific Publications
November 5, 2024
Charting the tumor antigen maps drawn by single-cell genomics
Scientific Publications
December 13, 2021